ArticleLeukemia & lymphoma2013
Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma.
Article in Leukemia & lymphoma, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Continuous induction with lenalidomide/dexamethasone versus autologous stem cell transplantation in newly diagnosed multiple myeloma: a case for response-adapted approach.Leukemia & lymphoma · 2022Trial
- High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma.Bone marrow transplantation · 2019Trial
- Prognostic factors in 448 newly diagnosed multiple myeloma receiving bortezomib-based induction: impact of ASCT, transplant refusal and high-risk MM.Bone marrow transplantation · 2024Article
- Perspectives on the Treatment of Multiple Myeloma.The oncologist · 2024Review
- Review
- Cryopreservation and storage patterns of hematopoietic progenitor stem cells for multiple myeloma.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2023Article
- Article
- Improved survival of multiple myeloma patients treated with autologous transplantation in the modern era of new medicine.Cancer science · 2021Observational
- Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant.Nature communications · 2020Article
- Multiple Myeloma in the Time of COVID-19.Acta haematologica · 2020Review
- Current role of high dose chemotherapy in the management of multiple myeloma.Leukemia & lymphoma · 2019Article
- Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement.Bone marrow transplantation · 2019Review
- Optimal chemo-mobilization for the collection of peripheral blood stem cells in patients with multiple myeloma.BMC cancer · 2019Article
- Stem-cell transplantation in multiple myeloma: how far have we come?Therapeutic advances in hematology · 2019Review
- Association Between Autologous Stem Cell Transplant and Survival Among Californians With Multiple Myeloma.Journal of the National Cancer Institute · 2019Observational
- The evolution of stem-cell transplantation in multiple myeloma.Therapeutic advances in hematology · 2018Review
- Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis.Leukemia · 2017Article
- Current Review on High-Risk Multiple Myeloma.Current hematologic malignancy reports · 2017Review
- Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy.Mayo Clinic proceedings · 2017Review
- First line vs delayed transplantation in myeloma: Certainties and controversies.World journal of transplantation · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Autologous stem cell transplant (ASCT) is an effective treatment for multiple myeloma (MM). However, the timing of ASCT in the era of novel agents (lenalidomide, thalidomide, bortezomib) is unknown. We retrospectively reviewed the outcome of patients with MM who received novel agent-based induction treatment and received first ASCT within 12 months of diagnosis (early ASCT, n = 102) or at a later date (late ASCT, n = 65). Median time to ASCT was 7.9 months vs. 17.7 months in early vs. late ASCT. The 3- and 5-year overall survival (OS) from diagnosis was 90 and 63% vs. 82 and 63% in early and late ASCT, respectively (p = 0.45). Forty-one and 36 patients in the early and late ASCT groups have relapsed or progressed, with median time to relapse of 28 and 23 months (p = 0.055). On multivariable analysis, factors predictive of increased risk for progression were International Scoring System (ISS) stage III (p = 0.007), and less than a very good partial response (< VGPR) post-ASCT (p < 0.001). A factor predictive of worst outcome for OS was being on hemodialysis (p = 0.037). No superiority of one agent was seen. In summary, early or late ASCT is a viable option for patients with MM receiving induction treatment with novel targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.